Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma

• Autores: Ouyang, Jing; Plütschow, Annette; Von Strandmann, Elke Pogge; Reiners, Katrin S.; Ponader, Sabine; Rabinovich, Gabriel Adrian; Neuberg, Donna; Engert, Andreas; Shipp, Margaret A.
• Año de publicación: 2013
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: Galectin-1; Hodgkin Disease; Prognosis; Elisa; Case Control-Studies; Neoplasm Staging
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

Galectin-1 (Gal1) is a member of a highly conserved family of carbohydrate-binding proteins. It modulates innate and adaptive immune responses and fosters tumor-immune escape. Hodgkin lymphoma (HL) Reed-Sternberg cells overexpress and secrete Gal1, which selectively kills T helper (Th)1 and Th17 cells and cytotoxic T cells and promotes the immunosuppressive Th2/regulatory T-cell–predominant HL microenvironment. We developed a sandwich enzyme-linked immunosorbent assay and assessed serum Gal1 levels in 293 newly diagnosed, previously untreated patients with classical HL (cHL) enrolled in 3 risk-adapted clinical trials. Serum Gal1 levels were significantly higher in patients with cHL than in normal controls (P < .0001). Gal1 serum levels also increased with Ann Arbor stage (P 5 .012), areas of nodal involvement (P < .0001), and the International Prognostic Score (2-7, P 5 .019). We conclude that Gal1 serum levels are significantly associated with tumor burden and related clinical features in newly diagnosed cHL patients.
Fil: Ouyang, Jing. No especifíca;
Fil: Plütschow, Annette. No especifíca;
Fil: Von Strandmann, Elke Pogge. No especifíca;
Fil: Reiners, Katrin S.. No especifíca;
Fil: Ponader, Sabine. No especifíca;
Fil: Rabinovich, Gabriel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina
Fil: Neuberg, Donna. No especifíca;
Fil: Engert, Andreas. No especifíca;
Fil: Shipp, Margaret A.. No especifíca;